Breakthrough Therapy Designation
Psilocybin Therapy
The active compound in "magic mushrooms," psilocybin is being studied for depression, anxiety, and end-of-life distress. It received FDA Breakthrough Therapy Designation for treatment-resistant depression.
50Clinical Trials
3Companies
6Legal States
FDA StatusBreakthrough Therapy Designation
Legal PathwayState-by-state regulation (OR, CO, NM)
Also Known Asmagic mushrooms, COMP360, psilocin
Legal Status by State
View full legal tracker →Fully Operational
Legal, Launching
Decriminalized
Active Legislation
Research Only
No Activity
Legal & Regulated4
AZCONMOR
Decriminalized2
DCMI
Pending Legislation11
AKCACTGAMANVNJNYTXVTWA
Clinical Trials
Phase 120
Phase 218
Phase 34
Active, Not Recruiting·Phase 2·psilocybin
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
University of Washington
AnxietyDepressionHematopoietic and Lymphatic System Neoplasm+1 more
Active, Not Recruiting·Phase 1·psilocybin
Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD
Scottsdale Research Institute
PTSD
Active, Not Recruiting·Phase 1·psilocybin
Psilocybin Brain Stimulation and Imaging Pilot Study
Johns Hopkins University
Healthy Volunteers
Active, Not Recruiting·N/A·psilocybin
Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism
Healing Advocacy Fund
Alcohol Use Disorder
Active, Not Recruiting·Phase 1·psilocybin
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
Centre for Addiction and Mental Health
Obsessive-Compulsive Disorder
Active, Not Recruiting·Phase 1·psilocybin
A Study of Psilocybin for PTSD
Johns Hopkins University
Post Traumatic Stress Disorder
Companies & Research
Organizations developing Psilocybin-based therapies